Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15404
UPID:
RSU1_HUMAN
Alternative names:
-
Alternative UPACC:
Q15404; A8KA46; D3DRU3; Q6FI17
Background:
Ras suppressor protein 1, identified by the accession number Q15404, plays a crucial role in the Ras signal transduction pathway. This protein is known for its ability to suppress v-Ras transformation in vitro, highlighting its potential impact on cellular signaling and growth regulation.
Therapeutic significance:
Understanding the role of Ras suppressor protein 1 could open doors to potential therapeutic strategies. Its involvement in the Ras pathway suggests a significant potential for targeting in cancer therapy, where Ras signaling is often dysregulated.